<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335526">
  <stage>Registered</stage>
  <submitdate>21/05/2010</submitdate>
  <approvaldate>18/06/2010</approvaldate>
  <actrnumber>ACTRN12610000505000</actrnumber>
  <trial_identification>
    <studytitle>Intravascular device administration sets: Replacement after Standard Versus Prolonged use (The RSVP Trial)</studytitle>
    <scientifictitle>Intravascular device (IVD) administration sets: a comparison of IVD-related Bloodstream Infection between Replacement after Standard Versus Prolonged use (The RSVP Trial)</scientifictitle>
    <utrn />
    <trialacronym>RSVP</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Intravascular device related blood stream infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients in this study have intravascular devices (IVDs) used in medical, surgical, intensive care, oncology and haematology units, and include adult and paediatric patients. Patients will have their administration set replaced every 4 days. This will continue for the course of their intravenous (IV) therapy.</interventions>
    <comparator>Patients will have their intravascular devices replaced every 7 days for the course of their IV therapy.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>IVD-related Bloodstream Infection (IVD-BSI): (1) Primary bacteraemia/fungaemia with &gt;=1 positive blood culture from a peripheral vein with no other identifiable source for the BSI other than the IVD, plus, one of: a positive semiquantitative (&gt;15cfu)  device culture, with the same organism (species and antibiogram) isolated from the device and blood, or (2) Two blood cultures (one from an IVD hub and one from a peripheral vein), that both meet the CRBSI criteria for differential time to positivity (DTP) (growth of the same microbe from hub drawn blood at least 2 hours before growth from the peripheral blood)</outcome>
      <timepoint>While IVD is in situ or within 48 hours of IVD removal</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>(i) IVD Colonisation: Growth of &gt;15 CFU from distal segment of IVD tip on removal, using the semiquantitative culture method</outcome>
      <timepoint>Tips cultured on device removal</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>(ii) Administration set (AS) colonisation: Growth of 10^3 CFU/ml from infusate taken from the AS.</outcome>
      <timepoint>On removal of AS.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All cause BSI: Any positive blood culture result</outcome>
      <timepoint>While the IVD is in situ, or within 48 hours of removal.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>(iv) All cause mortality: Mortality at hospital discharge</outcome>
      <timepoint>At hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>(v) Time the IVD was in situ.</outcome>
      <timepoint>At the time of IVD removal.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>vi) AS per patient.</outcome>
      <timepoint>Number of AS used from time of study entry to IVD removal</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>(vii) Costs. AS consumable prices, staff time and treatment costs for IVD-BSI.</outcome>
      <timepoint>For the period of hospitalisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Possible CRBSI: One or more positive blood cultures drawn through two or more lumens of an IVD, where one of the blood cultures has a colony count at least 3-fold greater than the colony count for the blood culture obtained from the second lumen.</outcome>
      <timepoint>Whilst IVD in situ or within 48 hours of removal.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Infusate Related bloodstream Infection (IRBSI): Concordant growth of the same organism from the infusate and blood cultures with no other identifiable source of infection</outcome>
      <timepoint>While IVD is in situ or within 48 hours of removal</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Informed written consent or waived consent (as per approving HREC) 2. Central venous or peripheral arterial IVD in situ. 3. IVD and AS have been insitu for 72-95 hours 4. IVD scheduled/expected use &gt; or =7 days</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Current bloodstream infection
Planned removal of device less than or equal to 24 hours
IVD in situ &gt;96 hours
Original AS already routinely replaced</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Computer generated allocation provided by electronic data collection device. Allocation is concealed until the patient is randomised</concealment>
    <sequence>Computer generated</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/05/2011</anticipatedstartdate>
    <actualstartdate>30/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/12/2016</actualenddate>
    <samplesize>2939</samplesize>
    <actualsamplesize>2941</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,WA</recruitmentstate>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Children's Hospital - Herston</hospital>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>Princess Margaret Hospital - Subiaco</hospital>
    <hospital>Lady Cilento Children's Hospital - South Brisbane</hospital>
    <hospital>St John of God Hospital, Murdoch - Murdoch</hospital>
    <postcode>6150 - Murdoch</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Griffith University</primarysponsorname>
    <primarysponsoraddress>Nathan Campus, 170 Kessels Road, Nathan QLD 4111</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Royal Brisbane and Women's Hospital Foundation</fundingname>
      <fundingaddress>1 Butterfield St, Herston QLD 4029</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Gold Coast Hospital Foundation</fundingname>
      <fundingaddress>108 Nerang St Southport Qld 4215</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress>Canberra, Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Nurses' Society of Australia</fundingname>
      <fundingaddress>8 Whitington Ave,
Glen Osmond SA 5064
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Australian College of Critical Care Nurses (Qld)</fundingname>
      <fundingaddress>Suite 1, 670 Canterbury Rd, Surrey Hills, Vic 3127
Postal address: Locked Bag 8, Surrey Hills, Vic 3127</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Griffith University</fundingname>
      <fundingaddress>170 Kessels Road, Nathan Qld 4111</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>IVD insertion is the most common invasive healthcare procedure with approximately 14 million IVDs used in Australia each year. IVDs alone are inadequate to deliver most therapy and require connection to an administration set. These IVD administration sets (AS) refer to infusion systems comprised of some or all of: tubing, fluid containers, pressure monitoring transducers, blood sampling ports, measuring burettes and extension tubing. IVDs and their AS break the natural defence barrier of the skin, and are the single most important cause of healthcare acquired blood stream infection (BSI).  Most IVD's are replaced every 3 -4 days , however preliminary research suggests routine replacement of AS every 4 days costs Australia about $1 billion annually, and some studies suggest 7 day use would reduce costs with no threat to patient safety.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Gold Coast Health Service District Human Research Ethics Committee via the Queensland Health Multi-Site Ethics review process</ethicname>
      <ethicaddress>Office of the Human Research Ethics Committee
Gold Coast Health Service District
Little High Street, Southport QLD 4215</ethicaddress>
      <ethicapprovaldate>4/11/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>10/06/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Children's Health Services Queensland Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 3, RCH Foundation Building
Royal Children's Hospital
Herston QLD 4029</ethicaddress>
      <ethicapprovaldate>16/12/2013</ethicapprovaldate>
      <hrec>HREC/13/QRCH/185</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethics review committee (RPAH zone)</ethicname>
      <ethicaddress>Research Development Office
Royal Prince Alfred Hospital
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>25/07/2012</ethicapprovaldate>
      <hrec>HREC/12/RPAH/337</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Group Human Reserach Ethics Committee</ethicname>
      <ethicaddress>Level 2 A Block
Hospital Avenue
Nedlands WA 6009</ethicaddress>
      <ethicapprovaldate>21/08/2013</ethicapprovaldate>
      <hrec>2012-183 approval SCGOPHCG</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Margaret Human Research Ethics Committee</ethicname>
      <ethicaddress>Princess Margaret Hospital
Roberts Road, Subiaco, Perth
Western Australia 6008</ethicaddress>
      <ethicapprovaldate>16/12/2014</ethicapprovaldate>
      <hrec>2014105EP</hrec>
      <ethicsubmitdate>24/11/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St John of God Health Care Human Research Ethics Committee</ethicname>
      <ethicaddress>St John of God Health Care Human Research Ethics Committee
C/o St John of God Subiaco Hospital
12 Salvado Road
Subiaco Western Australia 6008</ethicaddress>
      <ethicapprovaldate>12/08/2015</ethicapprovaldate>
      <hrec>Ref No. 825</hrec>
      <ethicsubmitdate>5/08/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Prof Claire Rickard</name>
      <address>Griffith Universtiy
170 Kessels Road,
Nathan QLD 4111</address>
      <phone>61 7 3735 6460</phone>
      <fax />
      <email>c.rickard@griffith.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Nicole Marsh, Project Manager</name>
      <address>Royal Brisbane and Women's Hospital</address>
      <phone>3636 8740</phone>
      <fax />
      <email>nicole_marsh@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Claire Rickard</name>
      <address>School of Nursing and Midwifery
Griffith University Nathan Campus N48_2.12
Nathan QLD 4111</address>
      <phone>+61 07 3735 6460</phone>
      <fax />
      <email>c.rickard@griffith.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>